2011 - IPITA - Prague


Parallel session 2 – Open oral presentations Topic: Results of clinical autologous and allogeneic islet transplantation

2.8 - Impact of aging on the in vivo potency of human islet preparation

Presenter: R., Misawa, Chicago, USA
Authors: R. Misawa, R.D. Molano, C. Fotino, E. Zahr-Akrawi, A. Miki, J. Molina, S. Barker, S. Villate, A. Khan, P. Witkowski, L. Inverardi, H. Ichii, C. Ricordi, A. Pileggi



Impact of aging on the in vivo potency of human islet preparation

 

R. Misawa1, R.D. Molano2, C. Fotino2, E. Zahr-Akrawi2, A. Miki2, J. Molina2, S. Barker2, S. Villate2, A. Khan2, P. Witkowski3, L. Inverardi2, H. Ichii2, C. Ricordi2, A. Pileggi2
1 University of Chicago, University of Miami, Chicago, Miami, USA; 2 University of Miami, Miami, USA; 3 University of Chicago, Chicago, USA

Objective: Islet transplantation into immunodeficient mice allows assessing cell viability and function, in the absence of allo-/auto-immunity. We sought to identify potential donor and isolation variables influencing in vivo islet functionality in the mouse bioassay.

Methods: For 175 human islet preparations, grafts of 2,000IEQ islets were implanted in the renal subcaspular space ofstreptozotocin-induced athymic nu/nu (nude) mice. Preparations were retrospectively divided into two groups: achieving or not diabetes reversal after transplant and univariate analysis was done for donor [age, gender, BMI, and cold ischemic time (CIT)] and isolation variables [yield (IEQ) and Islet Particle Number (IN), Average Particle Size (APS; IEQ/IN ratio) and digestion time]. Binary logistic regression identified significant predictors and carrying out partition analysis to optimize outcomes in mice. Conventional in vitro potency assays (viability by FDA/PI) and insulin stimulation index (SI) in glucose challenge were compared to the bioassay.

Results: From 175 mice transplanted with human islets, 137 achieved euglycemia. Univariate comparisons revealed a significant difference in donor age (reversal vs. non reversal: 38.92±1.12 vs.47.42±1.62, P<0.001), whereas no significant differences were observed in gender (M/F:85/43 vs. 29/18), BMI (28.64±0.46vs. 28.56±0.77) and CIT (644.2±22.0vs. 715.9±36.3). APS significantly differed (1.43±0.07 vs. 1.70±0.11, P<0.05). No significant differences were found in yield (283,476±13,930 vs. 264,217±23,792IEQ), IN (221,229±12,174 vs. 182,512±20,091) and Digestion Time (14.90±0.49 vs. 16.01±0.81). Binary logistic regression analysis identifiedsignificant differences in age (P<0.01; odds ratio=20.68) and CIT(P<0.05; OR=5.18) correlating with in vivo function. Partition analysis for bioassay and donorage demonstrated correlation with potency with diabetes reversal rates of 100% (age<23 years), 76% (23≦age<56), and 25% (age

Conclusions: Donor age may influence the outcome in vivo human islet function.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi